Please login to the form below

Not currently logged in
Email:
Password:

Shire experiences sales growth thanks to ADHD drug

Shire reported a rise in sales and revenues on the back of the success of new drugs such as the much-criticised medicine, Vyvanse, on February 21.

Shire reported a rise in sales and revenues on the back of the success of new drugs such as the much-criticised medicine, Vyvanse, on February 21.

Investors' concerns over the attention deficit and hyperactivity disorder (ADHD) treatment were alleviated as Shire reported a 41 per cent increase in sales at the end of 2007.

Total company revenues were up by 36 per cent of which 23 per cent was thanks to the sale of new medications.

Matthew Emmens, chief executive officer of Shire, said: "The launch of Vyvanse continues to progress well and we are confident about the medication's future growth supported by new clinical studies."

US-based researchers reported last year that ADHD drugs could stunt growth and did not improve behaviour over a sustained period of time [PMLive November 2007].

Emmens said: ëThe acquisition of New River Pharmaceuticals (April 2007) gave us full ownership and control of Vyvanse and this new generation ADHD treatment is establishing itself in the US, where it has already gained a market share of 6 per cent.î

22nd February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics